Genetic Analysis

Executive Summary

Genetic Analysis AS is a privately held, research-driven diagnostics company headquartered in Oslo, Norway, focused on developing innovative solutions for the rapidly expanding human microbiome market. Founded in 2008, the company leverages proprietary platforms to analyze microbial communities and deliver actionable insights for disease diagnosis, treatment monitoring, and precision medicine. With a strong emphasis on gut microbiome profiling, Genetic Analysis aims to address unmet needs in conditions such as inflammatory bowel disease, metabolic disorders, and oncology. The company's core technology integrates next-generation sequencing with advanced bioinformatics to provide accurate, reproducible, and scalable diagnostic tools for clinical and research use. Although financial details remain undisclosed, Genetic Analysis operates in a high-growth sector, with the global microbiome diagnostics market projected to expand significantly over the next decade. The company's position as an early mover in Norway's biotech ecosystem and its focus on regulatory compliance and clinical validation suggest potential for future commercial traction, though it faces competition from larger, well-funded players in the space.

Upcoming Catalysts (preview)

• Q3 2026CE Marking for a key microbiome diagnostic assay60% success
• TBDStrategic partnership or licensing deal with a pharmaceutical company40% success
• Q4 2026Series B or later-stage funding round to scale operations70% success